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Abstract 
Background: Evidence of probiotics effects on gut function, brain activity and emotional behaviour were provided. 
Probiotics can have dramatic effects on behaviour through the microbiome–gut–brain axis, through vagus nerve. We 
investigated whether chronic probiotic intake could modulate psychological state, eating behaviour and body composi-
tion of normal weight obese (NWO) and preobese–obese (PreOB/OB) compared to normal weight lean women (NWL).
Methods: 60 women were enrolled. At baseline and after a 3-week probiotic oral suspension (POS) intake, all 
subjects underwent evaluation of body composition by anthropometry and dual X-ray absorptiometry, and psycho-
logical profile assessment by self-report questionnaires (i.e. EDI-2, SCL90R and BUT). Statistical analysis was carried 
out using paired t test or a non-parametric Wilcoxon test to evaluate differences between baseline and after POS 
intake, one-way ANOVA to compare all three groups and, where applicable, Chi square or t test were used to assess 
symptoms.
Results: Of the 48 women that concluded the study, 24% were NWO, 26% were NWL and 50% were PreOB/OB. Sig-
nificant differences in body composition were highlighted among groups both at baseline and after a POS (p < 0.05). 
After POS intake, a significant reduction of BMI, resistance, FM (kg and %) (p < 0.05), and a significant increase of FFM 
(kg and  %) (p < 0.05) were observed in all subjects in NOW and PreOB/OB. After POS intake, reduction of bacterial 
overgrowth syndrome (p < 0.05) and lower psychopathological scores (p < 0.05) were observed in NWO and PreOB/
OB women. At baseline and after POS intake, all subjects tested were negative to SCL90R_GSI scale, but after treat-
ment subjects positive to BUT_GSI scale were significantly reduced (8.33%) (p < 0.05) compared to the baseline 
(33.30%). In NWO and PreOB/OB groups significant differences (p < 0.05) in response to the subscales of the EDI-2 
were observed. Significant improvement of the orocecal transit time was observed (p < 0.05) after POS intake. Fur-
thermore, significant differences were observed for meteorism (p < 0.05) and defecation frequency (p < 0.05).
Conclusions: A 3-week intake of selected psychobiotics modulated body composition, bacterial contamination, 
psychopathological scores of NWO and PreOB/OB women. Further research is needed on a larger population and for 
a longer period of treatment before definitive conclusions can be made.
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Background
The human gut hosts a dynamic and complex microbial 
ecosystem. It is represented by approximately 1 kg of bac-
teria in the average adult, about the weight of the human 
brain. It is composed by microorganisms belonging to 14 
families, 45 genera and 400–500 distinct species, vari-
ously distributed along the entire intestinal tract. Two 
bacterial phylotypes Firmicutes and Bacteroidetes are the 
most abundant bacteria species in the gut [1].
The microbiota–gut brain axis, recently termed “psy-
chobiota” [2], plays an important role in host physiology, 
as in the regulation of neuroinflammation, neuroendo-
crine stress response, neurodevelopment and modulation 
of mood and behavior [3–5], which implicates it in psy-
chiatric disorders, such as stress, anxiety and depression.
Nowadays, several studies identify the relationship 
between gut microbiota and the onset of various dis-
eases, demonstrating the ability of probiotics in control-
ling inflammatory processes, attenuation of metabolic 
dysfunctions, normalization of stress-induced abnormal 
behaviors, regulation of the hypothalamus–pituitary–
adrenal axis (HPA axis) and neuropsychiatric disorders 
[6–8].
The evidence of the inflammatory state alteration, high-
lighted in schizophrenia, major depressive disorder and 
bipolar disorder, strongly recalls the microbiota altera-
tion, suggesting an important role of the alteration of the 
gastrointestinal (GI) system also in neuropsychiatric dis-
orders [8].
Probiotics can have dramatic effects on behaviour, 
through their action on the vagus nerve and on the 
microbiome–gut–brain axis, which constitutes a bidi-
rectional communication network. Probiotics produce a 
variety of neurochemicals, analogues of mammalian hor-
mones, involved in mood and behaviour. Therefore, the 
visceral messages from the gut can affect brain function 
and, vice versa, signals from the brain may affect the sen-
sory system and the gut secretion mode.
The bacteria most commonly exploited as probiotics 
with psychotropic effects in animal models and human 
clinical trials have been classified as “psychobiotics” [2], 
and they belong to the Bifidobacterium and Lactobacillus 
families.
In the last few years, in vivo experiments demonstrated 
that administration of Bifidobacterium longum 1714 and 
Bifidobacterium breve 1205, Lactobacillus helveticus and 
Lactobacillus plantarum strain PS128 reduce anxiety and 
depression like behaviors, HPA axis hyperactivity and 
abnormal neurochemical changes [9].
Gut microbiota seems to have an impact on the sero-
tonergic system. In fact, treatment with Lactobacillus 
helveticus in hyperammonemia-treated rats led to an 
anxiolytic effect and improved cognitive function pos-
sibly through a reduction in hippocampal 5-Hydroxy 
Tryptamine (5HT) levels [10].
Moreover, a combined treatment with Lactobacillus 
helveticus and rhamnosus prevented intestinal perme-
ability alteration caused by stress [11].
Anxiety-like behavior associated with chronic colitis in 
mice was attenuated by B. longum administration, asso-
ciated with decreased hippocampal brain-derived neuro-
trophic factor (BDNF) mRNA [12, 13].
Although less evidence exists for probiotic actions 
on human population, it has been demonstrated that 
patients who received a probiotic formulation containing 
Lactobacillus acidophilus, Lactobacillus casei and Bifido-
bacterium bifidum, significantly decreased Beck Depres-
sion Inventory (BDI) scores [14]. Moreover, a probiotic 
mixture of Lactobacillus helveticus and Bifidobacterium 
longum and a probiotic-containing milk drink of Lacto-
bacillus casei showed positive effects on psychological 
distress [15, 16].
Furthermore, a growing body of scientific evidence 
supports the notion that the crosstalk between the gut 
microbiota, diet and immune system activates mediators 
and signalling pathways, which influence the whole body 
metabolism and disease [17–19]. The metabolic activi-
ties of the gut microbiota play a decisive part in obesity 
because of its role in the improvement of calorie extrac-
tion from food, the accumulation of substrates in adipose 
tissue, like fatty acids, and the utilization of energy and 
nutrients for its growth [20].
Obesity is characterized by a peculiar microbiota and 
the microbiota itself, together with the host genotype 
and lifestyle, could contribute to the development of this 
metabolic dysfunction. Also, a bidirectional association 
between obesity and self-reported or clinical measures of 
depression were observed, and body dissatisfaction was 
robustly associated as a risk factor for obesity and eating 
disorders [9].
Different obese phenotypes have been described based 
on body fat composition and distribution, rather than 
the simple increase of body weight, body mass index 
(BMI) and genetics [21]: (1) metabolically obese normal 
weight [22]; (2) metabolically healthy obese [23]; and (3) 
Trial registration ClinicalTrials.gov Id: NCT01890070
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metabolically unhealthy obese or “at risk” obese [24]; (4) 
normal weight obese (NWO) [25].
Subjects affected by NWO syndrome usually have a 
BMI value within the normal range (<25  kg/m2) and, 
at the same time, high total body fat percentage (TBFat 
>30%) and total body lean mass (TBLean) deficiency 
based on a genetic predisposition. They also have high 
oxidative stress level, early inflammatory status and some 
metabolic abnormalities [26–28]. Furthermore, in our 
previous study on female subjects affected by NWO syn-
drome it was highlighted, not only an increased risk of 
cardiovascular and metabolic disease, but also a will to 
control body weight, revealing a suppressed vocation for 
obesity. In fact, NWO subjects obtained an intermediate 
score on the eating disorder inventory-2 (EDI-2), particu-
larly in terms of body dissatisfaction and drive for thin-
ness, between normal weight lean women and pre-obese 
or obese women [28].
Up today very few studies demonstrated the beneficial 
effects on the health status of obese subjects with psychi-
atric illnesses and eating disorders of these “mind-alter-
ing” probiotics. Lactobacillus appears to reduce body fat 
mass, anxiety and dysphoria, and improves insulin sensi-
tivity and glucose tolerance [29, 30].
Nowadays, literature doesn’t report any paper focused 
on the effectiveness check of treatment with psychobiot-
ics in NWO syndrome.
Given the link among gut microbiota, body composi-
tion, the risk of eating disorder, anxiety- and depression-
like behaviours, the purpose of the current study was to 
test the efficacy of a 3-week administration of a psycho-
biotic oral suspension (POS), containing Streptococcus 
thermophilus, Bifidobacterium animalis subsp. Lactis, 
Streptococcus thermophiles, Bifidobacterium bifidum, 
Lactobacillus delbrueckii spp. Bulgaricus, Lactococcus 
lactis subsp. Lactis, Lactobacillus acidophilus, Lactoba-
cillus plantarum, Lactobacillus reuteri, selected accord-
ing to literature. The endpoints of this study were to 
evaluate the body composition parameters, the psycho-
logical profile, and eating behaviour changes of NWO 
and preobese–obese (PreOB/OB) compared to normal 
weight lean women (NWL), after POS.
Methods
Clinical study design and subjects
The clinical study was conducted using a randomized, 
double blinded controlled design, between October 
2015 and July 2016, according to the CONSORT flow-
chart (Fig.  1). Subjects were consecutively recruited 
within a program of routine medical check-up at the 
Section of Clinical Nutrition and Nutrigenomic, Depart-
ment of Biomedicine and Prevention of the University 
of Rome “Tor Vergata”, at “Nuova Annunziatella” Clinic, 
and General Hospital Foundation, Catholic University of 
Sacred Heart, Rome, Italy.
Sixty women were enrolled. Subjects were screened for 
eligibility at first medical visit and underwent body com-
position analysis, psychological profile and eating behav-
iour assessment by symptom checklist 90 (SCL90R), 
[31] for the evaluation of general psychopathology, body 
uneasiness test (BUT), for the evaluation of body image 
perception (IC) [32], and EDI-2, for eating behavior [33], 
in order to test the efficacy of a 3-week administration of 
POS on NWO and preobese–obese (PreOB/OB) com-
pared to normal weight lean women (NWL).
As the expected weight loss was below 5, according the 
Ethical Committee of the University of Rome “Tor Ver-
gata”, data from Dual X-ray Absorptiometry (DXA) was 
used to classified the subjects. We classified the subjects 
according to BMI, and TBFat % by DXA into: (a) NWL 
women, with a BMI <25  kg/m2 and TBFat % <30; (b) 
NWO women, with a BMI <25 kg/m2, and TBFat % ≥30; 
(c) PreOB/OB women, with a BMI ≥25 kg/m2 and TBFat 
% ≥30.
Body composition was assessed by Bioelectrical Imped-
ance Analysis (BIA) at baseline and after treatment.
Forty-eight subjects were eligible for the study and they 
were randomly divided into two groups (1:1 ratio). The 
randomization was determined by an external contract 
research organization and coordinated with the Section 
of Clinical Nutrition and Nutrigenomic, at the University 
of Rome “Tor Vergata”, independently of the investigators.
One intervention group (IG) and one control group 
(CG) were utilized and took daily n.1 bag of POS, or 
n.1 bag of placebo. The study consists of a 3-week treat-
ment, with POS or placebo, separated by a 3-week wash 
out period, used to avoid additive effects on treatments 
to follow. After 3 weeks of washout, the IG and CG were 
reversed. The IG and CG arms were double-blinded. 
Study period resulted in a total duration of 9 weeks. At 
the beginning and at the end of each arm (±3 days), the 
subjects had to repeat the visit.
Subjects were asked to maintain their usual lifestyle 
habits and to report any illness or abnormality aris-
ing during the study. At the end of each arm, a clinician 
assessed any adverse effects from the interventions by 
going through a checklist of symptoms, including bloat-
ing, fullness or indigestion, altered bowel habit, dizziness 
and other symptoms that were possibly associated with 
the interventions. Any adverse effect has been properly 
reported.
Exclusion criteria
Exclusion criteria included age <20 or >65  year, preg-
nancy, breast-feeding, type 1 diabetes, presence of intes-
tinal bacterial overgrowth, characterized by high levels 
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of hydrogen and methane production in the small bowel, 
acute diseases, endocrine disorders, liver, heart or kid-
ney dysfunctions, history of chronic degenerative or 
infectious diseases, medication, antibiotic therapy until 
10 days before enrolment, smoke, drug or alcohol abuse, 
participation in another diet trial. No subjects with 
known alterations to intestinal transit following organic 
pathologies (abdominal surgery, diabetes mellitus, 
Fig. 1 Study Flow Diagram according to Consort, 2010
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scleroderma, hypothyroidism, etc.) were included in the 
study. Subjects could not have taken antibiotics or pro-
biotics in the month before the study and were willing to 
avoid use of probiotics for the duration of the study.
Endpoints
The primary endpoint was the evaluation of body com-
position changes after POS by anthropometry, DXA, and 
bioimpedentiometry. The secondary endpoint was the 
evaluation of psychological profile by self-report ques-
tionnaires (i.e. EDI-2, SCL90R, and BUT). The third end-
point was the evaluation of orocaecal transit time and 
bacterial overgrowth by lactulose breath test (LBT).
Psychobiotics oral suspension (POS) and placebo capsules 
composition
1 bag of 3  g psychobiotics oral suspension (POS) con-
tained: Streptococcus thermophilus SGSt01 (1.5  ×  1010 
colony-forming unit CFU), Bifidobacterium animalis 
subsp. Lactis SGB06 (1.5  ×  1010 colony-forming unit 
CFU), Streptococcus thermophiles (1.5  ×  1010 colony-
forming unit CFU), Bifidobacterium bifidum SGB02 
(1.5  ×  1010 colony-forming unit CFU), Lactobacillus 
delbrueckii spp. Bulgaricus DSM 20081 (1.5 ×  1010 col-
ony-forming unit CFU), Lactococcus lactis subsp. Lactis 
SGLc01 (1.5  ×  1010 colony-forming unit CFU), Lacto-
bacillus acidophilus SGL11 (1.5  ×  1010 colony-forming 
unit CFU), Lactobacillus plantarum SGL07 (1.5  ×  1010 
colony-forming unit CFU), Lactobacillus reuteri SGL01 
(1.5 × 1010 colony-forming unit CFU), maltodextrin from 
corn, anti-caking agent (silica), casein, lactose and glu-
ten <3 ppm LLOQ (lower limit of quantitation) (Biocult 
strong, HOMEOSYN, Rome, Italy).
The placebo was represented by 3  g of inert material 
(flour type 00), maltodextrin from corn, anti-caking agent 
(silica). The appearance of the placebo was indistinguish-
able in colour, shape, size, packaging, smell, and taste 
from that of the probiotic supplement.
Both products were provided by HOMEOSYN (Rome, 
Italy).
Anthropometric measurements
At T1, after a 12-h overnight fast, all subjects underwent 
anthropometric evaluation (body weight, height, waist 
and hip circumferences), according to standard method 
[34]. All the individuals were instructed to take off their 
clothes and shoes before undergoing the measurements.
BMI was calculated using the formula: BMI  =  body 
weight (kg)/height (m)2.
Bioelectrical impedance analysis (BIA)
Resistance, reactance, impedance, phase angle, total body 
water (TBW), intracellular water (ICW), extracellular 
water (ECW), free fat mass (FFM) and fat mass (FM) 
were measured using a BIA phase sensitive system at 
50  kHz frequency (BIA 101S, Akern/RJL Systems-Flor-
ence, Italy).
Measurements were taken according to Di Renzo et al. 
[35].
Dual x‑ray absorptiometry
To assess body composition analysis, that give the pos-
sibility to measure TBFat and TBLean, DXA (i-DXA, GE 
Medical Systems, Milwaukee, WI, USA) evaluation was 
performed at baseline, according to De Lorenzo et  al. 
[28].
Psychodiagnostic instruments
Anonymous questionnaires, self-compiled, were given to 
all subjects for the collection of socio-demographic data. 
The symptom checklist 90 (SCL90R) [31] was adminis-
tered for the evaluation of general psychopathology, the 
body uneasiness test (BUT) for the evaluation of the per-
ception of body image (IC) [32] and the EDI-2, for eat-
ing behavior [33]. Eating behavior was assessed using the 
Italian version of the EDI-2, standardized in an Italian 
population [36]. The subscales of the EDI-2 include drive 
for thinness (DT), bulimia (B), body dissatisfaction (BD), 
ineffectiveness (I), interceptive awareness (IA), maturity 
fears (MF), asceticism (A), impulse regulation (IR), social 
insecurity (SI), perfectionism (P) and interpersonal dis-
trust (ID).
Body uneasiness test (BUT) It is a self-assessment 
scale, used for body image studies and related patholo-
gies. Beyond the total score, BUT allows to calculate the 
global severity index (GSI) or total average score, which is 
obtained from the sum of clinical scores (BUT a), divided 
by their number (34). Items number with score ≥1 corre-
spond to positive symptom total (PST). The sum of items 
scores ≥1 divided by PST, produces the positive symptom 
distress index (PSDI) [32].
Five factors were defined: WP—weight phobia, BIC—
body image concerns, A—avoidance, CSM—compulsive 
self-monitoring, D—depersonalization. In our study, we 
considered as positive for altered perception of body 
image a GSI score ≥1.2.
Symptom check list—revised (SCL90R) It is a general 
evaluation scale of the psychopathology, based on patient’s 
self-evaluation. This scale is composed by 90 items, which 
investigate the presence of symptoms in the week before 
the test check. These 90 items, which have five levels Lik-
ert answers, have 10 reference factors: (1) somatization 
(Som); (2) obsessive/compulsive (Obs); (3) interpersonal 
sensitivity (Interp Sens); (4) depression (Dep); (5) anxious 
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(Anx); (6) anger/hostility (Anger Host); (7) phobia (Phob); 
(8) psychoticism (Psych); (9) paranoia (Paran); (10) sleep 
disorders. The score goes from 0 to 4, and a score above 1 
is an index of pathology [31].
Breath testing and gastrointestinal symptoms 
questionnaire
Subjects also completed a questionnaire evaluating gas-
trointestinal symptoms (meteorism, abdominal pain, def-
ecation frequency/week).
The LBT was performed by administering 20  g lactu-
lose dissolved in 100  cc water to the subjects. Breath 
samples were obtained by asking the patients to blow into 
suitable containers at time 0 (before ingesting the lactu-
lose) and then every 15 min thereafter for the 4 h follow-
ing lactulose administration. Gas chromatography was 
used to assess the presence and quantity of hydrogen in 
the breath (Quintron Milwaukee, Wisconsin USA). Oro-
caecal transit time was calculated for each patient by 
constructing the curves of hydrogen in the breath over 
time. This therefore showed the time necessary for the 
bolus to reach the caecum [37].
Statistical analysis
The statistical analysis was carried out using IBM SPSS 
Statistics for Windows, Version 21.0 (Armonk, NY: IBM 
Corp). Data are expressed as mean  ±  standard devia-
tion (SD), and minimum and maximum. A paired t test 
or a non-parametric Wilcoxon test were performed to 
evaluate differences between baseline and after POS. A 
one-way ANOVA was carried out to compare the aver-
age of the responses obtained in all three groups. Where 
applicable, the Chi square or Student’s t test were used to 
assess symptoms.
A difference of p < 0.05 was considered significant.
Results
Of the 60 women initially recruited, 8 did not meet inclu-
sion criteria, 4 dropped out of the study voluntarily, leav-
ing a total of 48 subjects for final analysis.
The characteristics of the study population in terms 
of age, weight, height, BMI, body composition and psy-
chological profile (EDI-2, BUT, and SCL90R) are shown 
in Table  1. In particular, between the NWL and the 
NWO groups, significant differences (p < 0.05), in terms 
of weight (Δ% 14.31), BMI (Δ% 16.95), hip circumfer-
ence (Δ% 9.4), TBW (%) (Δ% −10.05), TBFat (%) (Δ% 
32.77), TBFat (g) (Δ% 43.43), FM (kg) (Δ% 58.59), FM 
(%) (Δ% 39.75) and FFM (%) (Δ% −10.13) were observed. 
Between the NWL and the PreOB/OB there were signifi-
cant differences (p < 0.05) in terms of weight (Δ% 25.06), 
BMI (Δ% 35.22), waist (Δ% 18.93) and hip circumference 
(Δ% 14.50), PA (°) (Δ%17.46), TBW (%), (Δ% −17.49), 
ECW (%) (Δ% −9.57), ICW (L) (Δ% 11.61), ICW (%) (Δ% 
7.65), TBFat (%) (Δ% 64.97), TBFat (g) (Δ% 125.08), FM 
(kg) (Δ% 64.32), FM (%) (Δ% 43.35) and FFM (%) (Δ% 
−11.04). Significant differences (p  <  0.05) between the 
NWO and the PreOB/OB groups in terms of weight (Δ% 
9.40), BMI (Δ% 15.62), Reactance (Ohm), (Δ% 19.73), 
PA (°) (Δ% 20.72), TBW (L) (Δ% −0.60), TBW (%) (Δ% 
−8.27), ECW (L) (Δ% −12.45), ECW (Δ% −11.70), and 
ICW (L) (Δ% 9.50), ICW (%) (Δ% 9.78), TBFat (%) (Δ% 
24.26) and TBFat (g) (Δ% 56.93) were observed (Table 1).
After 3  weeks of POS treatment, a significant reduc-
tion of BMI, resistance, reactance, PA, ICW (%), FM (kg 
and %) (p < 0.05), and a significant increase of TBW (L 
and %), ECW (L and %), ICW (L), FFM (kg) and FFM (%) 
were observed in NOW population. Furthermore, in Pre-
obOB group it was highlighted a significant reduction of 
weight, BMI, waist, hip, resistance, ECW (L and %), FM 
(kg and %), and a significant increase of PA, TBW (%), 
ICW (L and %), FFM (kg and %) (p < 0.05) (Table 1).
Significant differences (p < 0.05) were observed among 
the NWL, NWO and PreOB/OB groups in body compo-
sition parameters after POS treatment (Table 1).
At baseline, the total tested sample was negative to 
SCL90R_GSI scale and 33.30% of the population was 
positive at BUT_GSI scale (GSI ≥1.2; mean 0.96 ± stand-
ard deviation 0.66). After 3 weeks of POS treatment, all 
population remained negative to SCL90R_GSI scale, 
and the positive to BUT scale was significantly reduced 
(p  <  0.05) at 8.33% (GSI ≥1.2; mean 0.59  ±  standard 
deviation 0.52). At baseline, among the 33.3% of the posi-
tive to BUT_GSI and BUT_CSM scale, the 12.5% were 
NWL, the 50% were NWO, and 37.55% were PreOB/OB. 
After POS treatment only NWO among the 8.33% of the 
positive (100%) were identified.
The average scores of the various dimensions and the 
total score of SCL90R scale, BUT_GSI and EDI-2 are rep-
resented in Table 2. After 3 weeks of POS treatment, in 
the general population significant differences (p  <  0.05) 
in terms of the responses to the subscales of the EDI-2 
were observed: −37.98 Δ% of B (baseline, 1.74  ±  3.01; 
3 weeks POS, 1.08 ± 2.06), the −15.95 Δ% of DT (base-
line, 1.74 ± 3.01; 3 weeks POS, 1.08 ± 2.06), the −40.15 
Δ% of I (baseline, 1.74 ± 3.01; 3 weeks POS, 1.08 ± 2.06). 
After POS treatment, in the NWO group significant 
differences (p  <  0.05) in terms of the responses to the 
subscales of the EDI-2 were observed: −41.94 Δ% of B 
(baseline, 0.91  ±  1.64; 3  weeks POS, 0.53  ±  1.16), the 
−19.30 Δ% of DT (baseline, 9.29 ±  7.81; 3  weeks POS, 
7.50 ± 7.18), the −50.45 Δ% of I (baseline, 3.26 ± 4.29; 
3 weeks POS, 1.62 ± 2.85). After 3 weeks of POS treat-
ment, in the PreOB/OB group significant differences, 
(p  <  0.05) in terms of responses to the subscales of 
the EDI-2, were observed: −31.25 Δ% of B (baseline, 
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Table 1 Comparison of body composition parameters of normal weight lean, normal weight obese and pre-obese/obese 
groups between baseline and after 3 weeks POS treatment
Results are expressed in mean value ± standard deviation, and minimum and maximum for each parameter. Values of p < 0.05 are considered significant
BMI body mass index, ECW extracellular water, FM fat mass, FFM fat free mass, ICW intracellular water, NWL normal weight lean, NWO normal weight obese, PA phase 
angle, PreOB/OB preobese–obese, TB total body, TBW total body water
a NWO T0 vs T1 p < 0.05; b PreOB/OB T0 vs T1 p < 0.05 c NWL T0 vs T1. For Anova-test at baseline p < 0.05; ¤ NWL vs NWO p < 0.05; ¥ NWO vs PreOB/OB p < 0.05; ° NWL 
vs PreOB/OB p < 0.05. Anova-test after POS p < 0.05; Ϫ NWL vs NWO p < 0.05; Ϭ NWO vs PreOB/OB p < 0.05; ϣ NWL vs PreOB/OB p < 0.05
NWL NWO PreobOB
Baseline POS Baseline POS Baseline POS
Age (years) 30.18 ± 2.04 (28.00–33.00) 40.00 ± 12.56 (27.00–56.00) 33.57 ± 10.57 (24.00–50.00)
Height (cm) 164.64 ± 4.03 (160.00–170.00) 162.90 ± 6.60 (154.00–168.00) 158.33 ± 1.86 (155.60–160.00)
Weight (kg) 55.55 ± 4.65¤,° 
(50.50–62.50)
54.84 ± 5.63Ϫ,ϣ 
(49.20–63.00)
63.50 ± 3.97¥ 
(59.00–68.30)
63.10 ± 3.27 
(59.00–66.60)
69.47 ± 6.07 
(63.80–78.00)
63.35 ± 0.16b 
(63.20–63.50)
BMI (kg/m2) 20.47 ± 1.04¤,° 
(19.48–22.41)
20.49 ± 1.40Ϫ,ϣ 
(18.98–22.59)
23.94 ± 0.93¥ 
(22.74–24.88)
23.80 ± 0.84a,Ϭ 
(22.92–24.88)
27.68 ± 1.92 
(25.56–30.47)
25.78 ± 0.48b 
(25.32–26.23)
Waist (cm) 67.41 ± 4.22 
(64.50–75.00)°
67.98 ± 4.60Ϫ,ϣ 
(63.80–75.00)
74.25 ± 5.08 
(69.50–79.00)
75.33 ± 4.70 
(70.00–81.00)
80.17 ± 8.02 
(73.00–91.00)
73.75 ± 2.35b 
(71.50–76.00)
Hip (cm) 94.09 ± 4.57 ¤,° 
(87.00–97.00)
93.23 ± 4.35 Ϫ,ϣ 
(87.50–97.00)
103.25 ± 5.61¥ 
(98.00–108.50)
101.00 ± 3.72Ϭ 
(98.00–106.00)
107.73 ± 0.54 
(107.00–108.20)
106.75 ± 0.78b 
(106.00–
107.50)
Resistance (Ohm) 595.89 ± 85.36 
(501.00–735.00)
598.33 ± 69.50 ϣ 
(497.00–690.00)
576.67 ± 55.46 
(526.00–650.00)
567.00 ± 53.60a 
(513.00–636.00)
565.13 ± 35.34 
(526.00–611.00)
523.00 ± 24.02b 
(500.00–
546.00)
Reactance (Ohm) 66.00 ± 12.24 
(56.00–87.00)
65.89 ± 8.46 
(56.00–73.00)
61.33 ± 7.74¥ 
(53.00–71.00)
59.67 ± 8.75a,Ϭ 
(51.00–71.00)
73.43 ± 9.54 
(66.00–89.00)
69.50 ± 6.79 
(63.00–76.00)
PA (°) 6.30 ± 0.35° 
(5.90–6.80)
6.29 ± 0.46ϣ 
(5.70–6.80)
6.13 ± 0.89¥ 
(5.30–7.30)
6.03 ± 0.97a,Ϭ 
(5.10–7.30)
7.40 ± 0.59 
(6.70–8.30)
7.55 ± 0.37b 
(7.20–7.90)
TBW (L) 31.80 ± 2.83 
(29.10–36.60)
31.66 ± 3.00 
(29.70–36.90)
33.13 ± 2.50¥ 
(31.10–36.50)
33.40 ± 2.56a 
(31.10–36.80)
32.93 ± 0.36 
(32.60–33.50)
33.35 ± 1.10 
(32.30–34.40)
TBW (%) 57.92 ± 4.19¤,° 
(50.80–61.30)
57.82 ± 3.19 
(52.40–60.40)
52.10 ± 1.37¥ 
(50.30–53.40)
52.90 ± 2.01a 
(50.60–55.30)
47.79 ± 4.30 
(42.00–52.60)
52.65 ± 1.83b 
(50.90–54.40)
ECW (L) 14.11 ± 1.33 
(12.40–16.10)
14.07 ± 1.39 
(12.60–16.10)
15.10 ± 2.01¥ 
(12.50–17.10)
15.37 ± 2.18a,Ϭ 
(12.50–17.40)
13.22 ± 0.74 
(12.10–14.00)
13.20 ± 0.84b 
(12.40–14.00)
ECW (%) 44.42 ± 1.38° 
(42.50–46.00)
43.93 ± 2.64ϣ 
(40.80–47.20)
45.53 ± 3.93¥ 
(40.40–49.30)
45.87 ± 4.29a,Ϭ 
(40.30–50.10)
40.17 ± 2.02 
(37.10–42.60)
39.50 ± 1.36b 
(38.20–40.80)
ICW (L) 17.66 ± 1.63° 
(16.70–20.50)
17.59 ± 1.86ϣ 
(16.20–20.80)
18.00 ± 1.45¥ 
(16.10–19.40)
18.03 ± 1.47a, Ϭ 
(16.10–19.40)
19.71 ± 0.63 
(18.90–20.60)
20.15 ± 0.26b 
(19.90–20.40)
ICW (%) 55.58 ± 1.38° 
(54.00–57.50)
55.62 ± 1.91ϣ 
(52.92–57.58)
54.50 ± 3.91¥ 
(50.70–59.60)
54.12 ± 4.37a,Ϭ 
(49.85–59.81)
59.83 ± 2.02 
(57.40–62.90)
60.61 ± 1.37b 
(59.30–61.92)
TBFat (%) 26.55 ± 2.83¤,° 
(24.10–29.00)
– 35.25 ± 1.44¥ 
(33.90–36.60)
– 43.80 ± 0.00 
(43.80–43.80)
–
TBFat (kg) 15.15 ± 0.01¤,° 
(15.14–15.16)
– 21.73 ± 1.73¥ 
(20.11–23.34)
– 34.10 ± 0.00 
(34.10–34.10)
–
TBLean (kg) 40.17 ± 5.98 
(34.99–45.35)
– 37.61 ± 0.57 
(37.08–38.14)
– 41.26 ± 0.00 
(41.26–41.26)
–
FM (kg) 11.35 ± 2.86¤,° 
(8.10–15.10)
11.80 ± 3.12c,Ϫ,ϣ 
(8.10–16.00)
18.00 ± 1.64 
(15.90–19.70)
17.27 ± 1.80a 
(15.80–19.70)
18.65 ± 0.99 
(17.70–19.60)
16.95 ± 0.99b 
(16.00–17.90)
FM (%) 20.30 ± 4.06¤,° 
(16.10–26.40)
21.05 ± 4.43c,Ϫ,ϣ 
(16.50–27.80)
28.37 ± 2.09 
(26.90–31.20)
27.57 ± 2.58a 
(25.00–30.90)
29.10 ± 1.36 
(27.80–30.40)
26.70 ± 1.46b 
(25.30–28.10)
FFM (kg) 44.23 ± 3.57 
(42.20–50.00)
43.75 ± 4.06 
(41.10–50.30)
45.50 ± 3.25 
(43.10–49.90)
45.83 ± 3.32a 
(43.20–50.30)
45.50 ± 0.63 
(44.90–46.10)
46.40 ± 0.84b 
(45.60–47.20)
FFM (%) 79.70 ± 4.06¤,° 
(73.60–83.90)
78.95 ± 4.43c,Ϫ,ϣ 
(72.20–83.50)
71.63 ± 2.09 
(68.80–73.10)
72.43 ± 2.58a 
(69.10–75.00)
70.90 ± 1.36 
(69.60–72.20)
73.30 ± 1.46b 
(71.90–74.70)
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Table 2 Comparison of  psychometric parameters of  normal weight lean, normal weight obese and  pre-obese/obese 
groups of women between baseline and after 3 weeks POS treatment
NWL NWO PreobOB
Baseline POS Baseline POS Baseline POS
EDI-2_DT 2.89 ± 4.63 
(0.00–20.00)
2.94 ± 4.40 
(0.00–19.00)
5.26 ± 6.33 
(0.00–21.00)
5.09 ± 6.08 
(0.00–20.00)
8.41 ± 7.58 
(0.00–18.00)
8.50 ± 7.84 
(0.00–19.00)
EDI-2_B 1.00 ± 2.45 
(0.00–10.00)
0.39 ± 1.24 
(0.00–5.00)
0.91 ± 1.64 
(0.00–7.00)
0.53 ± 1.16a 
(0.00–5.00)
3.64 ± 4.12 
(0.00–16.00)
2.50 ± 2.89b 
(0.00–10.00)
EDI-2_BD 5.28 ± 6.09 
(0.00–23.00)
4.94 ± 6.01 
(0.00–23.00)
9.29 ± 7.81 
(0.00–27.00)
7.50 ± 7.18a 
(0.00–25.00)
14.09 ± 6.35 
(2.00–24.00)
11.91 ± 5.76b 
(0.00–20.00)
EDI-2_I 1.39 ± 2.20 
(0.00–6.00)
1.22 ± 1.90 
(0.00–5.00)
3.26 ± 4.29 
(0.00–17.00)
1.62 ± 2.85a 
(0.00–10.00)
5.82 ± 4.92 
(1.00–19.00)
3.68 ± 4.51b 
(0.00–16.00)
EDI-2_P 3.83 ± 3.54 
(0.00–14.00)
3.61 ± 3.16 
(0.00–13.00)
4.85 ± 3.00 
(0.00–11.00)
4.74 ± 2.99 
(0.00–12.00)
3.36 ± 3.67 
(0.00–14.00)
3.32 ± 3.81 
(0.00–15.00)
EDI-2_ID 2.33 ± 2.47 
(0.00–9.00)
2.06 ± 2.39 
(0.00–9.00)
3.53 ± 3.55 
(0.00–16.00)
3.47 ± 3.67 
(0.00–17.00)
3.68 ± 3.37 
(0.00–10.00)
3.59 ± 3.45 
(0.00–10.00)
EDI-2_IA 3.61 ± 3.96 
(0.00–12.00)
3.22 ± 3.61 
(0.00–11.00)
4.47 ± 5.93 
(0.00–23.00)
4.41 ± 6.03 
(0.00–24.00)
5.36 ± 5.02 
(0.00–16.00)
5.27 ± 4.73 
(0.00–15.00)
EDI-2_MF 7.89 ± 5.14 
(1.00–21.00)
7.67 ± 4.98 
(1.00–20.00)
5.76 ± 3.24 
(0.00–14.00)
5.59 ± 3.28 
(0.00–15.00)
5.50 ± 4.59 
(1.00–20.00)
5.45 ± 4.27 
(1.00–19.00)
EDI-2_A 3.50 ± 2.46 
(0.00–8.00)
3.56 ± 2.50 
(0.00–9.00)
3.53 ± 1.97 
(0.00–7.00)
3.38 ± 1.97 
(0.00–8.00)
4.50 ± 2.09 
(1.00–8.00)
4.27 ± 2.07 
(0.00–7.00)
EDI-2_IR 1.61 ± 2.48 
(0.00–9.00)
1.67 ± 2.28 
(0.00–8.00)
3.50 ± 3.86 
(0.00–14.00)
3.68 ± 4.09 
(0.00–15.00)
2.32 ± 2.92 
(0.00–9.00)
2.27 ± 2.81 
(0.00–9.00)
EDI-2_SI 2.39 ± 2.17 
(0.00–7.00)
2.33 ± 2.00 
(0.00–6.00)
4.03 ± 3.38 
(0.00–15.00)
3.94 ± 3.20 
(0.00–14.00)
4.00 ± 3.41 
(0.00–14.00)
3.91 ± 3.38 
(0.00–15.00)
SCL90R_Som 0.67 ± 0.12 
(0.50–0.83)
0.30 ± 0.15c 
(0.08–0.50)
0.61 ± 0.35 
(0.33–1.08)
0.28 ± 0.11a 
(0.17–0.42)
0.87 ± 0.63 
(0.08–1.67)
0.42 ± 0.26b 
(0.17–0.67)
SCL90R_Obs Comp 0.81 ± 0.36 
(0.50–1.30)
0.37 ± 0.13c 
(0.30–0.60)
0.60 ± 0.23 
(0.30–0.80)
0.27 ± 0.10a 
(0.20–0.40)
0.46 ± 0.34 
(0.20–1.00)
0.20 ± 0.00b 
(0.20–0.20)
SCL90R_Interp Sens 0.75 ± 0.41 
(0.22–1.33)
0.22 ± 0.23c 
(0.00–0.56)
0.56 ± 0.09 
(0.44–0.67)
0.26 ± 0.11a 
(0.11–0.33)
0.45 ± 0.29 
(0.11–0.89)
0.56 ± 0.00b 
(0.56–0.56)
SCL90R_Dep 0.70 ± 0.35 
(0.38–1.31)
0.27 ± 0.26c 
(0.00–0.69)
0.18 ± 0.04 
(0.15–0.23)
0.26 ± 0.10 
(0.15–0.38)
0.52 ± 0.67 
(0.08–1.62)
0.23 ± 0.24 
(0.00–0.46)
SCL90R_Anx 0.56 ± 0.34 
(0.12–1.00)
0.17 ± 0.15 
(0.10–0.43)
0.30 ± 0.22 
(0.04–0.57)
0.31 ± 0.14 
(0.21–0.50)
0.66 ± 0.42 
(0.03–1.19)
0.08 ± 0.08b 
(0.00–0.16)
SCL90R_Anger Host 0.50 ± 0.22 
(0.17–0.67)
0.20 ± 0.07c 
(0.17–0.33)
0.39 ± 0.16 
(0.17–0.50)
0.17 ± 0.14a 
(0.00–0.33)
0.78 ± 0.49 
(0.00–1.33)
0.17 ± 0.17b 
(0.00–0.33)
SCL90R_Phob 0.10 ± 0.17 
(0.00–0.43)
0.06 ± 0.13 
(0.00–0.29)
0.33 ± 0.19 
(0.14–0.57)
0.19 ± 0.07a 
(0.14–0.29)
0.37 ± 0.56 
(0.00–1.29)
0.07 ± 0.07b 
(0.00–0.14)
SCL90R_Paran 0.82 ± 0.63 
(0.00–1.67)
0.31 ± 0.27c 
(0.00–0.67)
0.17 ± 0.25 
(0.00–0.50)
0.00 ± 0.00a 
(0.00–0.00)
0.39 ± 0.32 
(0.00–0.83)
0.17 ± 0.17b 
(0.00–0.33)
SCL90R_Psych 0.26 ± 0.18 
(0.10–0.60)
0.06 ± 0.08 
(0.00–0.18)
0.26 ± 0.17 
(0.11–0.49)
0.15 ± 0.13a 
(0.00–0.31)
0.34 ± 0.40 
(0.00–0.98)
0.08 ± 0.08b 
(0.00–0.16)
SCL90R_GSI 0.58 ± 0.23 
(0.29–0.92)
0.23 ± 0.07c 
(0.17–0.32)
0.45 ± 0.20 
(0.23–0.69)
0.25 ± 0.02a 
(0.22–0.27)
0.54 ± 0.38 
(0.14–1.13)
0.24 ± 0.12b 
(0.13–0.36)
BUT_GSI 0.55 ± 0.43 
(0.09–1.21)
0.39 ± 0.43c 
(0.12–1.15)
1.11 ± 0.66 
(0.24–1.71)
0.79 ± 0.64 
(0.15–1.62)
1.08 ± 0.69 
(0.41–2.09)
0.54 ± 0.41b 
(0.15–0.94)
BUT_WP 0.93 ± 0.82 
(0.13–2.38)
0.79 ± 1.05 
(0.13–2.63)
1.96 ± 1.17 
(0.38–2.88)
1.42 ± 1.27 
(0.38–3.13)
1.97 ± 0.60 
(1.13–2.75)
1.13 ± 0.65b 
(0.50–1.75)
BUT_BIC 0.58 ± 0.62 
(0.11–1.56)
0.37 ± 0.56c 
(0.00–1.33)
1.48 ± 0.85 
(0.44–2.44)
1.00 ± 0.78 
(0.22–2.00)
1.27 ± 1.20 
(0.11–3.00)
0.67 ± 0.58b 
(0.11–1.22)
BUT_A 0.18 ± 0.20 
(0.00–0.50)
0.04 ± 0.07c 
(0.00–0.17)
0.28 ± 0.22 
(0.00–0.50)
0.11 ± 0.16a 
(0.00–0.33)
0.13 ± 0.14 
(0.00–0.33)
0.17 ± 0.17b 
(0.00–0.33)
BUT_CSM 0.71 ± 0.48 
(0.00–1.33)
0.57 ± 0.30 
(0.17–1.00)
1.06 ± 0.67 
(0.17–1.67)
0.89 ± 0.87 
(0.00–2.00)
0.99 ± 0.73 
(0.17–1.83)
0.33 ± 0.35b 
(0.00–0.67)
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3.64 ± 4.12; 3 weeks POS, 2.50 ± 2.89), the −15.48 Δ% of 
DT (baseline, 14.09 ± 6.35; 3 weeks POS, 11.91 ± 5.76), 
the −36.72 Δ% of I (baseline, 5.82 ± 4.92; 3 weeks POS, 
3.68 ± 4.51) (Table 2).
A significant improvement of the orocaecal transit time 
and gastrointestinal symptoms were observed (p < 0.05) 
after 3 weeks of POS treatment respect to placebo. More-
over, significant differences were observed for meteorism 
(p < 0.05) and defecation frequency (p < 0.05) (data not 
show).
Discussion
The link between the “somatic” and “mental” is undeni-
ably a subject that has fascinated through the years and 
until the present day many artists and philosophers. Also 
researchers and scientists daily make their contribution 
to reveal this chimera showing a complex but fascinating 
harmonic unit.
The gut–microbiota–brain axis includes the central 
nervous system, neuroendocrine and neuro-immune sys-
tem, the sympathetic and parasympathetic arms of the 
autonomic nervous system, the enteric nervous system 
and, most importantly, the intestinal microbiota [38]. 
Some bacteria within the human gastrointestinal tract 
have the capacity to produce many neurotransmitters 
and neuromodulators, such as norepinephrine, serotonin, 
dopamine, acetylcholine, histamine and gamma-amin-
obutyric acid [7]. Due to these new evidences about the 
fundamental role of gut microbiota in the alteration of 
immune, neural and endocrine pathways, the so-called 
“gut–brain axis” is acquiring new significance, even if the 
communication routes are not yet defined [38].
From clinical experience and from the literature it is 
clear the importance of “personalization” of treatment, 
also respect to the individuals we have in care, taking 
into account body composition, gut microbiota, feed-
ing behaviour, attitude towards food and the presence of 
emotional states that may influence them. The intake of 
probiotic influences the secretion of molecules on which 
depend anxiety and depression, and simultaneously 
affects neuroendocrine response to stress.
Recent data show the strong correlation between dys-
biosis and a variety of conditions such as obesity, aller-
gies, autoimmune disorders, Irritable Bowel Syndrome, 
Inflammatory Bowel Disease and psychiatric disorders 
[39, 40]. Bifidobacterium and Atopobium were signifi-
cantly less abundant in obese animals compared to the 
non-obese rats, in conjunction with significantly higher 
levels of the Clostridium cluster XIVa and Lactobacil-
lus group [41]. In the meantime, Cani et  al. reported a 
reduction in the Clostridium cluster XIVa (Clostridium 
coccoides) group, along with lower Bifidobacterium and 
Bacteroides levels in mice fed high-fat diet. An increase 
of Firmicutes levels was observed in high-fat fed mice, 
while Bacteroides phylum decreased overtime in obese 
animals [42]. Angelakis et  al. [43], highlighted elevated 
levels of Bacteroidetes phylum, a strong abundance of the 
Firmicutes phylum and elevated concentrations of Lac-
tobacilli in the gut microbiota of obese and overweight 
adults compared to lean individuals. Moreover, the sup-
plementation with lactic acid bacteria brought to weight 
modification, suppression of the neuroendocrine stress 
response and relieved abdominal dysfunction [44, 45].
Consistent with these considerations, it has been pre-
pared a new formulation of POS, containing different 
strain of bacteria, i.e. Streptococcus thermophiles, Bifi-
dobacterium animalis subsp. Lactis, Streptococcus ther-
mophiles, Lactobacillus bulgaricus, Lactococcus lactis 
subsp. Lactis, Lactobacillus acidophilus, Lactobacillus 
plantarum, Lactobacillus reuteri, for a total of 120 × 1010 
colony-forming unit CFU.
We tested the effectiveness of this new POS formula-
tion, having two main purposes: (1) to investigate the 
correlation between body composition and the presence 
of psychological disorders and psychopathological symp-
toms in people affected by NWO syndrome and obesity 
Results are expressed in mean value ± standard deviation, and minimum and maximum for each parameter. Values of p < 0.05 are considered significant
A asceticism, A avoidance, Anger Host anger/hostility, Anx anxious, B bulimia, BD body dissatisfaction, BIC body image concerns, BMI body mass index, BUT body 
uneasiness test, CSM compulsive self-monitoring, D depersonalization, Dep depression, DT drive for thinness, EDI-2 eating disorder inventory-2, GSI global severity 
index, I ineffectiveness, IA interoceptive awareness, IC body image, ID interpersonal distrust, IG intervention group, Interp Sens interpersonal sensitivity, IR impulse 
regulation, MF maturity fears, NWL normal weight lean, NWO normal weight obese, Obs obsessive/compulsive, P perfectionism, Paran paranoia, Phob phobia, POS 
probiotic oral suspension, PreOB/OB preobese–obese, PSDI positive symptom distress index, PST positive symptom total, Psych psychoticism, SCL90R symptom 
checklist 90, SI social insecurity, Som somatization, WP weight phobia
a NWO T0 vs T1 p < 0.05; b PreOB/OB T0 vs T1 p < 0.05; c NWL T0 vs T1
Table 2 continued
NWL NWO PreobOB
Baseline POS Baseline POS Baseline POS
BUT_D 0.13 ± 0.10 
(0.00–0.20)
0.00 ± 0.00c 
(0.00–0.00)
0.13 ± 0.20 
(0.00–0.40)
0.13 ± 0.20 
(0.00–0.40)
0.57 ± 0.75 
(0.00–1.80)
0.10 ± 0.10b 
(0.00–0.20)
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respect to normal lean individual; (2) to check whether 
the intake of POS could change all the examined parame-
ters, in order to make an early diagnosis and to block any 
nascent development of a psychopathological disorder, 
taking into account all its future consequences.
In the present study, the cut-off point of total body fat 
was 30% [46]; the analysis of anthropometric and body 
composition values showed 24% of NWO, 26% of NWL 
and 50% of PreOB/OB women. In particular, between the 
NWL versus the NWO group, were highlighted several 
significant differences (p  <  0.05), like weight, BMI, hip 
circumference, TBW (%), TBFat (% and g), FM (kg and 
%) and FFM (%), as well as in NWL versus the PreOB/OB 
group, in terms of weight, BMI, waist and hip circumfer-
ence, PA (°), TBW (%), ECW (%), ICW (L and %), TBFat 
(% and g), FM (kg and %) and FFM (%) (p < 0.05).
Moreover, significant differences (p  <  0.05) between 
the NWO and the PreOB/OB groups in terms of weight, 
BMI, Reactance, PA, TBW (L and %), ECW (L and %), 
ICW (L and %), TBFat (% and g) were observed.
As a challenge in the development of effective strate-
gies to prevent the increased prevalence of obesity, 
data reported in this study highlight the efficacy of the 
POS treatment on body composition in subjects with 
more than 30% of total body fat, given the considerable 
improvement of BMI, FM (kg and %), hydration status 
as TBW, ECW and ICW, and FFM (p  <  0.05) in NWO 
group, as well as the improvement of weight, BMI, waist, 
hip, resistance, PA, TBW, ICW ECW, FM, and FFM in 
the PreobOB group (p < 0.05), suggesting a safe and effec-
tive intervention for general population, with substantial 
benefits to public health.
Many neurotransmitters and neuromodulators 
secreted by bacteria are able to modulate the state of the 
host mood: gamma-aminobutyric acid is produced by 
certain Lactobacillus and Bifidobacterium species; nor-
epinephrine is released by Escherichia, Bacillus and Sac-
charomyces spp.; 5 Hydroxy Triptamine is released by 
Candida, Streptococcus, Escherichia and Enterococcus 
spp.; dopamine is produced by Bacillus and acetylcholine 
by Lactobacillus [47]. Dinan et al. have reported that pro-
biotic Bifidobacterium infantis 35624 has shown to have 
an antidepressant action in preclinical models of depres-
sion acting as a psychobiotic with a mental health benefit 
[48]. Gut composition is affected also by the resilience 
to environmental stress, impairing the cortisol awaking 
response and emotional reaction in healthy subjects [49]. 
On the other hand, it has been shown that psychological 
stress itself leads to dysbiosis [50, 51], turning in a vicious 
circle.
Our results seem to confirm the high prevalence 
of body image disorders in NWO and PreoOB/OB 
patients. According to literature data, we provided the 
evidence that POS therapy improves the psychological 
state, reducing the positivity to BUT (−24.90%) and 
the alteration of body image perception, as demon-
strated by the significant reduction in the subscales of 
the EDI-2 responses both in NWO than in PreOB/OB 
(−41.94 Δ% of B, the −19.30 Δ% of DT, the −50.45 Δ% 
of I in NWO; −31.25 Δ% of B, the −15.48 Δ% of DT in 
PreOB/OB).
It has been demonstrated that the oral administra-
tion of the probiotic Bifidobacterium longum NCC3001 
(Morinaga, Japan) is able to prevent the anxiety-like 
behavior associated with gut inflammation in animals 
with an intact vagus nerve [51], as did Lactobacillus 
rhamnosus and Lactobacillus hilgardii [52]. Lactobacillus 
reuteri prevented the physiological signs of visceral pain, 
with a reduction in cardio-autonomic response [53], and 
Bifidobacterium lactis decreased visceral hypersensitiv-
ity when colorectal distention occurred in the context of 
psychological stress.
Hence, the lactulose passes intact the stomach and 
small intestine, and reaches the caecum, where the bac-
teria (normally present in the colon flora) break it down, 
leading to the production of hydrogen. Part of the hydro-
gen that forms is absorbed by the intestinal mucous and 
therefore enters the bloodstream before being released 
at the pulmonary alveoli and expired. By evaluating the 
time at which hydrogen appears in the breath, we are 
indirectly able to determine orocaecal transit time [35]. 
After POS treatment, a reduction of bacterial overgrowth 
(p  <  0.05) was observed in NWO and PreOB/OB when 
compared to controls. After POS therapy, a statistically 
significant improvement was seen in the intestinal transit 
time in all subjects. An increase in the number of weekly 
defecations and a reduction of meteorism in subjects 
affected by constipation were recorded.
Conclusions
A 3-week intake of selected probiotics, by modulat-
ing body composition, bacterial contamination, psy-
chopathological scores and eating behaviour of women 
affected by NWO syndrome and obesity, offers a tracta-
ble approach to problems related to obesity, psychologi-
cal state and unhealthy eating. One improvement of this 
study may be to extend the administration period of POS, 
as probiotics need several weeks to proliferate.
Despite the limitations of our study, related to the study 
design and the low sample size, our results highlighted 
that this new formulation of POS may possibly have 
potential as a therapeutic strategy for prevention and/
or treatment of certain eating behaviour disorders and 
anxiety-like conditions, to avoid a worsening of the psy-
chiatric symptomatology, the establishment of a global 
functional impairment of the subject and to improve the 
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quality of life of patients. Moreover, these results high-
light the need for a more detailed psychiatric evaluation 
of subjects with an alteration of body image perception, 
even when this alteration does not fit into a previous pat-
tern referred as eating disorder.
Further research is needed on a larger population and 
for a longer period of treatment with a controlled trial 
before definitive conclusions can be made.
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